Cargando…

The Incidence and Timing of Blood Cultures in Multiple Myeloma – Results from a Retrospective, Single Center, Real-World Study

Detalles Bibliográficos
Autores principales:	Szabo, Agoston Gyula, Iversen, Katrine Fladeland, Rosenvinge, Flemming Schønning, Möller, Sören, Plesner, Torben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Atlantis Press 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432406/ https://www.ncbi.nlm.nih.gov/pubmed/34595458 http://dx.doi.org/10.2991/chi.k.200719.001

Ejemplares similares

The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
por: Szabo, Agoston Gyula, et al.
Publicado: (2019)

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies
por: Szabo, Agoston Gyula, et al.
Publicado: (2023)

High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4(+) T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
por: Iversen, Katrine Fladeland, et al.
Publicado: (2022)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
por: Harsløf, Mads, et al.
Publicado: (2023)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB
por: Hiemstra, Ida H., et al.
Publicado: (2023)

Real-world renal function among patients with multiple myeloma in the United States
por: Mikhael, Joseph, et al.
Publicado: (2021)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59
por: Brennan, Kieran, et al.
Publicado: (2022)

Identifying “Real” Patients in the Real World
por: Callahan, Sean J.
Publicado: (2020)

Real world and hyper reality
por: Gautret, Philippe, et al.
Publicado: (2021)

Reply to Callahan: Identifying “Real” Patients in the Real World
por: Dempsey, Timothy M.
Publicado: (2020)

Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
por: Zhang, Jing, et al.
Publicado: (2020)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

Artificial intelligence for malaria: Bridging the gap for real world usage
por: FAN, Bingwen Eugene, et al.
Publicado: (2022)

Maribavir for Cytomegalovirus Treatment in the Real World—Not a Silver Bullet
por: Fung, Monica, et al.
Publicado: (2022)

Real-world impact of the COVID-19 pandemic on the assessment of anaesthesiology residents
por: Kealey, Alayne, et al.
Publicado: (2020)

Medication adherence in Fabry patients treated with migalastat: Real world experience
por: Riccio, Eleonora, et al.
Publicado: (2023)

Low Incidence of Reinfection With Endemic Coronaviruses Diagnosed by Real-Time PCR
por: Ringlander, Johan, et al.
Publicado: (2020)

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China
por: Li, Qian, et al.
Publicado: (2023)

Clinically meaningful benefit: real world use compared against the American and European guidelines
por: Dreicer, Jessica J., et al.
Publicado: (2017)

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
por: Zeng, Jing-Xin, et al.
Publicado: (2021)

Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
por: Liu, Zhao-Yun, et al.
Publicado: (2023)

Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan
por: Tsukune, Yutaka, et al.
Publicado: (2017)

Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
por: Feher, Michael, et al.
Publicado: (2021)

Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia
por: Kulkarni, Uday P., et al.
Publicado: (2022)

Clinical efficacy of tacrolimus in systemic lupus erythematosus with various manifestations: a real-world study
por: Bai, Wei, et al.
Publicado: (2022)

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
por: Khan, Shamis, et al.
Publicado: (2022)

Safety and pharmacokinetic profile of apixaban in end‐stage renal disease: A real‐world analysis
por: Tseng, Chen I., et al.
Publicado: (2022)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

RWD26 Real World Evidence for the Impact of COVID-19 Pandemic on the Incidence of Multiple Myeloma in Germany
por: Schilling, S, et al.
Publicado: (2022)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
por: Zhu, Yanan, et al.
Publicado: (2022)

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
por: Yang, Peiyu, et al.
Publicado: (2022)

Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma
por: Kamat, Siddhesh, et al.
Publicado: (2022)

In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
por: Worth, Heinrich, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6onnuqv9tav8ji4dd30u1i1j04